[The diagnosis, biopsy and treatment follow-up via ultrasound in patients with prostatic carcinoma].

According to data available in the literature prostate cancer accounts for 0.2 to 0.4 percent of all cancer diseases, 1 to 5 per cent of all tumors in males and 29.2 per cent of the tumors affecting the urogenital system. The consensus today is that prostate cancer is the most common tumor of the urogenital system. It is a disease of the advanced age, being most common in the age group 60 to 70. It is pointed out that transrectal echography has gained acceptance basically for the diagnosis of prostate cancer, for determining its stage and for check-up of the effect of treatment. According to M. Devonec et al., J. Pointes et al, the specificity of this method is 79 per cent and its sensitivity 48 per cent. The echographic diagnostic criteria for prostate cancer are described. The value of transrectal echography increases when performed with biopsy specimen examination under ultrasound control, especially in nonpalpable neoplasms or when digitally directed biopsy specimens have yielded doubtful or negative result. The method is noninvasive, practicable and well tolerated; this makes it particularly valuable for control of the effect of treatment.